Literature DB >> 22677639

Effect of glucocorticoid (triamcinolone acetonide) pretreatment in a murine penetrating keratoplasty and suture model.

Yang K Cho1, Hironori Uehara, Jason R Young, Bonnie Archer, Balamurali K Ambati.   

Abstract

PURPOSE: To evaluate the effect of glucocorticoid (triamcinolone acetonide injectable suspension) pretreatment on corneal neovascularization, lymphangiogenesis, and inflammation in a murine penetrating keratoplasty (PK) and corneal suture model.
METHODS: For the PK model, BALB/c mice were used as recipients and C57BL/6 mice were used as donors. A group pretreated with subconjunctival glucocorticoid and a combination of post-subconjunctival and topical glucocorticoids (group I) was compared with two groups that did not receive glucocorticoid pretreatment [one group received a combination of subconjunctival and topical glucocorticoids postoperatively (group II) and the other group received only topical glucocorticoid treatment postoperatively (group III)]. All groups were treated with subconjunctival glucocorticoid on the day of surgery. For the corneal suture model, BALB/c mice were used. A group receiving only pre-suture glucocorticoid treatment (group A) and a group receiving only post-suture glucocorticoid treatment (group C) were compared with a control group that did not receive glucocorticoid therapy (group B). The degree of neovascularization, lymphangiogenesis, and inflammatory infiltration was compared in each of these models.
RESULTS: In the PK model, the group receiving glucocorticoid pretreatment (group I) showed less neovascularization compared with the posttreatment-only groups (group II, P=0.043; group III, P=0.020) and less lymphangiogenesis compared with group III (P=0.005). In the corneal suture model, the glucocorticoid pretreatment group showed a similar level of neovascularization, lymphangiogenesis, and inflammatory infiltration as the posttreatment-only groups (P>0.05).
CONCLUSIONS: Glucocorticoid pretreatment before PK decreases neovascularization and lymphangiogenesis compared with posttransplant glucocorticoid treatment alone.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22677639      PMCID: PMC3443542          DOI: 10.1097/ICO.0b013e3182473356

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  37 in total

1.  Intraocular dexamethasone delivery system for corneal transplantation in an animal model.

Authors:  Fumie Kagaya; Tomohiko Usui; Kazutaka Kamiya; Yasuo Ishii; Sumiyoshi Tanaka; Shiro Amano; Tetsuro Oshika
Journal:  Cornea       Date:  2002-03       Impact factor: 2.651

2.  Subconjunctival injection of triamcinolone acetonide in the management of corneal graft rejection and new vessels.

Authors:  Ioannis Athanasiadis; Deric de Wit; Michael Tsatsos; Amit K Patel; Anant Sharma
Journal:  J Clin Pharmacol       Date:  2011-04-19       Impact factor: 3.126

Review 3.  Treatments for corneal neovascularization: a review.

Authors:  Deepak Gupta; Chris Illingworth
Journal:  Cornea       Date:  2011-08       Impact factor: 2.651

Review 4.  High-risk corneal allografts and why they lose their immune privilege.

Authors:  Jerry Y Niederkorn
Journal:  Curr Opin Allergy Clin Immunol       Date:  2010-10

5.  The effect of perioperative allergic conjunctivitis on corneal lymphangiogenesis after corneal transplantation.

Authors:  T H Flynn; M Ohbayashi; M Dawson; D F P Larkin; S J Ono
Journal:  Br J Ophthalmol       Date:  2011-06-07       Impact factor: 4.638

6.  Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty.

Authors:  C Cursiefen; H Wenkel; P Martus; A Langenbucher; N X Nguyen; B Seitz; M Küchle; G O Naumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2001-07       Impact factor: 3.117

7.  Single perioperative subconjunctival steroid depot versus postoperative steroid eyedrops to prevent intraocular inflammation and macular edema after cataract surgery.

Authors:  Myrthe Dieleman; René J Wubbels; Marina van Kooten-Noordzij; Peter W T de Waard
Journal:  J Cataract Refract Surg       Date:  2011-09       Impact factor: 3.351

8.  Histopathological study of delayed regraft after corneal graft failure.

Authors:  Leonardo N Santos; Leticia Rielo de Moura; Bruno F Fernandes; Devinder P Cheema; Miguel N Burnier
Journal:  Cornea       Date:  2011-02       Impact factor: 2.651

9.  VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment.

Authors:  Claus Cursiefen; Lu Chen; Leonardo P Borges; David Jackson; Jingtai Cao; Czeslaw Radziejewski; Patricia A D'Amore; M Reza Dana; Stanley J Wiegand; J Wayne Streilein
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

10.  Outcomes of repeat penetrating keratoplasty and risk factors for graft failure.

Authors:  Daniel J Weisbrod; Marisa Sit; Joel Naor; Allan R Slomovic
Journal:  Cornea       Date:  2003-07       Impact factor: 2.651

View more
  4 in total

1.  Presurgical corticosteroid treatment improves corneal transplant survival in mice.

Authors:  Hyun Kyung Kim; Jin A Choi; Hironori Uehara; Xiaohui Zhang; Balamurali K Ambati; Yang Kyung Cho
Journal:  Cornea       Date:  2013-12       Impact factor: 2.651

2.  Effect of trapping vascular endothelial growth factor-A in a murine model of dry eye with inflammatory neovascularization.

Authors:  Jin Woo Kwon; Jin A Choi; Eun Young Shin; Tae Yoon La; Dong Hyun Jee; Yeon Woong Chung; Yang Kyung Cho
Journal:  Int J Ophthalmol       Date:  2016-11-18       Impact factor: 1.779

3.  Soluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity.

Authors:  Nirbhai Singh; Michelle Tiem; Ryan Watkins; Yang Kyung Cho; Ying Wang; Thomas Olsen; Hironori Uehara; Christina Mamalis; Ling Luo; Zackery Oakey; Balamurali K Ambati
Journal:  Blood       Date:  2013-03-08       Impact factor: 22.113

4.  Lymphatic vessels identified in failed corneal transplants with neovascularisation.

Authors:  Michael Adam Diamond; Sze Wah Samuel Chan; Xun Zhou; Yelena Glinka; Eileen Girard; Yeni Yucel; Neeru Gupta
Journal:  Br J Ophthalmol       Date:  2018-10-22       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.